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the older method. Potential for drug accumulation was more
readily apparent in the simulated data using the new formu-
las. The spreadsheets used for the two methods appeared
practically identical.
Conclusion: Consideration should be given to using these
AUC formulas and adjusted targets unless all infusions are
given strictly over 30min.
doi:10.1016/j.ijid.2008.05.1080
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Background: There are no published information on tige-
cycline potency and spectrum from isolates from Indonesia.
As a component of the SENTRY Antimicrobial Surveillance
Program (Asia-Paciﬁc Region), we evaluated the activity
of tigecycline tested against recent (2006) isolates from
Indonesia by reference MIC methods.
Methods: Non-duplicate strains were consecutively col-
lected from three medical centres in Indonesia. All isolates
were tested against tigecycline using validated commercial
broth microdilution panels (TREK Diagnostics), with con-
current acceptable quality control and CLSI interpretations
(M100-S18) for comparison agents. Tigecycline breakpoints
published by the United States - Food and Drug Adminis-
tration were applied for each indicated species or genus,
and the proposed/provisional Acinetobacter spp. breakpoint
(≤2mg/L) per Jones et al. (2007) was applied
Results: A total of 383 (307 Gram-negative and 76 Gram-
positive) isolates were evaluated. Tigecycline was highly
active against the top 10 most frequently isolated non-
pseudomonal pathogens which comprised 82% of all strains.
The highest tigecycline MIC90 results (2mg/L were recorded
for non-indicated species, Proteus-Providencia. P. aerug-
inosa was also not signiﬁcantly inhibited by tigecycline
(MIC90, >8mg/L; data not shown)
Conclusions: Tigecycline demonstrated excellent activity
against all the commonly isolated pathogens from Indonesia,
including those being multidrug-resistant to other antimi-
crobial classes. Tigecycline shows promise for therapy of
indicated, antimicrobial-resistant species in this nation and
indeed, the entire Asia-Paciﬁc region.
doi:10.1016/j.ijid.2008.05.1081
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Background: Tigecycline is a glycylcycline class agent
recently introduced into clinical practice worldwide as an
alternative therapy for various evolving multidrug-resistant
(MDR) bacterial infections. China, Hong Kong (HK) and Tai-
wan medical centers (14) were monitored in 2006 by the
SENTRY Program for tigecycline spectrum/susceptibility and
compared to more than 25 agents.
Methods: CLSI methods were used for testing 2,595 iso-
lates with US-FDA (tigecycline product package insert) and
CLSI (M100-S18) breakpoints applied. Resistance phenotypes
were screened per CLSI M100-S18 and genotypic-resistances
by sequencing when required. Tigecycline was not active
against P. aeruginosa (MIC50, >4g/ml), data not shown
Results: Among 2,595 strains processed, the most fre-
quently tested pathogens and resistance patterns were:
S. aureus (545, 40% MRSA) > E. coli (366, 52% ESBL)>
K. pneumoniae (265, 33% ESBL) > E. faecalis (218,
linezolid resistance detected) > A. baumannii (211,
29% carbapenem-resistant) >S. pneumoniae (175, 27/80%
penicillin/macrolide-resistant) > E. faecium (169, 2.4%
VanA-type glycopeptide resistance). Fluoroquinolone resis-
tance was very high among E. coli (64%), K. pneumoniae
(21%) and A. baumannii (62%). MRSA rates varied by
nation: Hong Kong and China (38%) and Taiwan (69%),
but oxacillin resistance did not effect tigecycline activ-
ity. Metallo--lactamases were noted in Enterobacteriaceae
(<1%). Tetracycline resistance was frequent (30—86%) in
Gram-positive and -negative organisms; but no tigecycline-
resistant or non-susceptible strains were detected among
indicated species except for enterococci (2.3%)
Conclusions: Tigecycline retained high activity and treat-
ment potential against MDR pathogens tested from China,
Hong Kong and Taiwan. Continued monitoring of the tigecy-
cline class agents in these nations appears prudent as the
glycylcyclines become widely used.
doi:10.1016/j.ijid.2008.05.1082
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Background: Tigecycline has been marketed in Australia
for over one year. As part of the SENTRY Antimicrobial
Surveillance Program (Asia-Paciﬁc Region), we evaluated the
